Navigation Links
Geneticure Will Present Promising Data on Improving Treatment for Hypertension at the American Society for Pharmacology and Experimental Therapeutics Annual Meeting
Date:3/28/2016

MINNEAPOLIS, March 28, 2016 /PRNewswire/ -- Geneticure, LLC is a Minnesota-based pharmacogenomics testing company enabling the promise of personalized medicine by helping healthcare providers determine the right course of treatment for patients suffering from hypertension. The company will present data from their phase-I clinical trial at the American Society for Pharmacology and Experimental Therapeutics Annual Meeting in San Diego, California on April 3, 2016.

Photo - http://photos.prnewswire.com/prnh/20160328/348430

The results from Geneticure's retrospective study demonstrate that the patented Geneticure Hypertension Panel would have significantly reduced the time to achieve optimal blood pressure control and would have reduced the number of clinic visits for patients being treated for hypertension. Researchers found that the strongest associations between blood pressure control and genetics were between genes that are important in sodium regulation and the patient's response to a diuretic. In addition, researchers also found that drug metabolizing genes, along with genes that encode receptors essential in the regulation of heart rate and contractility of the heart, were strongly associated with the use of a drug called a beta-blocker.

The 14 gene Geneticure Hypertension Panel assesses hypertension treatment in a comprehensive integrative nature, from drug metabolizing enzymes to receptors that are important in the function of the heart, blood vessels, and kidneys, with a focus on and appreciation for the complexity of disease. The presentation of this data is a key differentiating step for Geneticure because there are several newly-developed pharmacogenetics companies which have yet to conduct clinical trials specific to their genetic panels.

"Without this data, it will be difficult to become a viable and widely utilized clinical test," says Eric Snyder, PhD, chief operating officer for Geneticure. "The FDA, clinical organizations, and clinical practice teams want scientific rigor in the clinical tests that they use, rather than the test makers simply pointing to previous research that assessed the panel in pieces."

"Additionally, the strategy of simply assessing drug metabolizing enzymes as a 'shotgun'  approach to pharmacogenomics falls short of the true goal of personalized medicine because it ignores the integrative nature of disease and the number of receptors, proteins, and organ systems  involved in addition to the drug metabolizing enzymes," adds Snyder. "What clinicians are asking for are tests that provide clear and concise reporting of actionable results paired with approved drug regimens. Targeted panels of highly functional genes that have been through clinical trials are the only way to ensure a seamless integration into the clinic and a large impact to the patient."

The findings from the study can have significant impact in the way hypertension (high blood pressure) is treated. Some 78 million Americans have high blood pressure with 5 million new diagnoses each year but more than 50 percent do not have it under control. Hypertension is one of the most preventable contributors to disease and death in the world but remains the most common condition in the primary care setting. Often billions of dollars are wasted in medical settings trying to treat hypertension simply because doctors typically use the same drug and dose as a starting point for every patient and then correct prescriptions over time based on how well patients do or don't react to it. This leads to a trial and error method of treating patients with prescriptions that could be ineffective or harmful. Patients then suffer through months of useless prescriptions and repeat office visits before getting their condition under control.

Geneticure's research utilizes unique markers in each individual's genetic code, which after testing the DNA will determine how well their body will respond to a particular drug and dose. The DNA testing is a simple cheek swab at the doctor's office and once the results are back, doctors are better able to prescribe the correct drug and dosage, saving patients time and money and improving their overall health. For more information about the company and their research, visit Geneticure.com.

About Geneticure, LLC

Geneticure, founded in 2012 and based in Minnetonka, Minnesota, is a pharmacogenomics testing company dedicated to achieving the decades-long promise of personalized medicine. The company focuses on helping healthcare providers get the unique genetic information they need to determine the right course of treatment for patients suffering from hypertension. For more information, visit Geneticure.com.

Contact Information

Scott Snyder or Ben Bowman
info@geneticure.com
http://www.geneticure.com
952-449-5242

This content was issued through the press release distribution service at Newswire.com. For more info visit: http://www.newswire.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/geneticure-will-present-promising-data-on-improving-treatment-for-hypertension-at-the-american-society-for-pharmacology-and-experimental-therapeutics-annual-meeting-300242108.html


'/>"/>
SOURCE Geneticure, LLC
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Cumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York
2. Bayer to Present New Data Across Oncology Portfolio at ASCO 2013
3. Arno Therapeutics to Present Positive, New Data Supporting the Potential of Onapristone in Endometrial and Breast Cancers at ASCO 2013 Annual Meeting
4. ASCO 2013: Boehringer Ingelheim to Present Data Across Multiple Cancers, Including Different Treatment Settings for Advanced NSCLC
5. Boehringer Ingelheim Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC
6. Amgen Highlights Data To Be Presented At American Society of Clinical Oncology Annual Meeting
7. AbbVie to Present Data on Investigational Anti-Cancer Compounds at American Society of Clinical Oncology Annual Meeting
8. Asmacure to Present Four Posters on Novel Pulmonary Development Compound ASM-024 at American Thoracic Society 2013 International Conference
9. Actinium Pharmaceuticals Clinical Results to be Presented at 8th International Symposium on Targeted Alpha Therapy Conference
10. AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference
11. Amgen To Present At The UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... Fla. , May 22, 2017  As ... as a whole continue to make the revolutionary ... becomes increasingly important for ensuring positive patient outcomes ... industry stakeholders are shifting focus away from clinical ... and effects of long-term specialty drug therapy utilization ...
(Date:5/15/2017)... 15, 2017 Enterin Inc., a privately-held CNS pharmaceutical ... novel compounds to treat Parkinson,s disease (PD), has enrolled the ... Phase 1/2a randomized, controlled, multicenter study involving patients with PD ... 50 patients over a 9-to-12-month period. The first stage is ... with PD. Participating sites include Denver , ...
(Date:5/10/2017)... Global Health Intelligence (GHI), the leading healthcare data analytics ... 2017 ranking of the Best-Equipped Hospitals in Latin America ... GHI,s hospitals database for Latin America , which is ... database covers 86% of the hospitals in Latin ... each institution in key areas such as beds, medical specialties, ...
Breaking Medicine Technology:
(Date:5/26/2017)... MA (PRWEB) , ... May 26, 2017 , ... On ... Act (AHCA), which narrowly passed the U.S. House on May 4, would result in ... be expected under continued implementation of the 2010 Patient Protection and Affordable Care Act ...
(Date:5/26/2017)... Illinois (PRWEB) , ... May 26, 2017 , ... Silver ... The community, which is located on more than four acres of land at 5620 ... independence. , The 103,000 square-foot building includes 125 studio and one-bedroom apartments. Each ...
(Date:5/26/2017)... ... May 26, 2017 , ... “When the Stars Lead Home”: a poignant ... of published author Laura Weigel Douglas, an avid reader who lives in the Pacific ... sometimes feels like Green Hills Adventure Camp. She couldn’t be more grateful. , Twelve-year ...
(Date:5/26/2017)... ... ... Happened in the Garden of Eden”: retells the stories of three Bible figures in modern ... author, Penelope Colt, mother, trader, horse farmer, artist and a former GM journeyman. Born ... At six, they moved to Dayton, Ohio, where Penny graduated high school. At sixteen, ...
(Date:5/24/2017)... , ... May 24, 2017 , ... ... Medical Center CEO Mary Ellen, hospital employees, and town officials to celebrate the ... The facility was developed by Rendina as part of its ongoing relationship with ...
Breaking Medicine News(10 mins):